Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
April 21, 2022
Vancouver, BC [April 21, 2022] – Canada’s Digital Technology Supercluster is excited to be
January 10, 2022
Ensuring all cancer patients have access to next-generation cancer treatment selection and recurrence monitoring requires a fundamental shift in how and where care is delivered.
December 13, 2021
With a strategic investment from Canada’s Digital Technology Supercluster, a pilot project to bring ctDNA testing into the Canadian health system was launched in July 2020.
November 11, 2021
Liquid biopsy is a powerful tool for matching cancer patients with targeted therapies and for cancer recurrence monitoring.
November 4, 2021
The use of genomic profiling and testing in cancer is helping clinicians and patients better understand the key drivers of a patient’s tumour and inform more precise treatment decisions.
November 1, 2021
FOUNTAIN VALLEY, Calif.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.